Definium Therapeutics (NASDAQ:DFTX – Get Free Report) and HAVN Life Sciences (OTCMKTS:HAVLF – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.
Institutional & Insider Ownership
27.9% of Definium Therapeutics shares are owned by institutional investors. 2.3% of Definium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Definium Therapeutics and HAVN Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Definium Therapeutics | N/A | -100.30% | -69.22% |
| HAVN Life Sciences | N/A | N/A | N/A |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Definium Therapeutics | 1 | 0 | 12 | 2 | 3.00 |
| HAVN Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
Definium Therapeutics currently has a consensus price target of $37.92, suggesting a potential upside of 72.30%. Given Definium Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Definium Therapeutics is more favorable than HAVN Life Sciences.
Earnings and Valuation
This table compares Definium Therapeutics and HAVN Life Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Definium Therapeutics | N/A | N/A | -$183.79 million | ($2.49) | -8.84 |
| HAVN Life Sciences | N/A | N/A | N/A | N/A | N/A |
Summary
Definium Therapeutics beats HAVN Life Sciences on 6 of the 8 factors compared between the two stocks.
About Definium Therapeutics
-inc-logo-1200x675.jpg?v=20240515130629){kind=logo}
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
About HAVN Life Sciences
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.
Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
